Skip to main content

Prognostic Significance of Left Ventricular Hypertrophy Regression

  • Chapter
Hypertension and the Heart

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 432))

Abstract

In hypertension, left ventricular hypertrophy (LVH) is initially a useful compensatory process, that represents an adaptation to increased ventricular wall stress; however, it is also the first step toward the development of overt clinical disease, such as congestive heart failure, cardiac dysrrhythmias, and ischemic heart disease. In fact, the Framingham Study has shown that once LVH is recognized clinically it constitutes a powerful independent risk factor for future cardiovascular morbid events whether assessed by ECG or echocardiography, the latter being a specific, repeatable and far more sensitive measure of LVH1,2. The echocardiographic technique has demonstrated that the geometric adaptation of the left ventricle to increased cardiac load may be different among patients. Concentric hypertrophy is characterized by increased mass and increased relative wall thickness, whereas eccentric hypertrophy is characterized by increased mass and relative wall thickness < 0.45; on the other hand, concentric remodeling occurs when there is increased thickness with respect to radius, without increased LV mass. Concentric hypertrophy appears to carry the highest risk and eccentric hypertrophy an intermediate risk, whereas concentric remodeling is probably associated with a smaller, albeit still consistent risk3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kannel WB, Gordon T, Offut T. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Ann. Int. Med., 71: 89 (1969).

    PubMed  CAS  Google Scholar 

  2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J Med, 322: 1561–1566 (1990).

    Article  PubMed  CAS  Google Scholar 

  3. Koren MJ Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med, 114: 345–352 (1991).

    PubMed  CAS  Google Scholar 

  4. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure, 1: 201–211 (1992).

    Article  Google Scholar 

  5. Sen S, Tarazi RC. Reversal of myocardial hypertrophy and influence of the adrenergic system. Am J Physiol, 244: H97–H101 (1983).

    PubMed  CAS  Google Scholar 

  6. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. lack of association to blood pressure control. Am J Cardiol, 49: 759–801 (1982).

    Google Scholar 

  7. Drayer JIM, Gardin JM, Weber MA, Aronow WS. Cadiac muscle mass during vasodilation therapy in hypertension. Clin Pharmacol Ther, 33: 727–732 (1983).

    Article  PubMed  CAS  Google Scholar 

  8. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Reversal of cardiac hypertrophy by long term treatment with calcium antagonists in hypertensive patients. J Cardiovasc Pharmacol, 12(suppl 6): 75–77 (1988).

    Article  Google Scholar 

  9. Dahlöf B, Pennert K, Hansson L. Reversal of Left Ventricular Hypertrophy in Hypertensive Patients. A Metaanalysis of 109 Treatment Studies. Am J Hypertens, 5: 95–110 (1992).

    PubMed  Google Scholar 

  10. Cruickshank J.M., Lewis J, Moore V, Dodd A. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Human Hypertens, 6: 85–90 (1992).

    CAS  Google Scholar 

  11. Agabiti-Rosei E, Muiesan ML, Castellano M. Methodology of studies on reversal of left ventricular hypertrophy. High Blood Press, 2(suppl 1): 11–13 (1993).

    Google Scholar 

  12. Schmieder AM. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double blind studies. JAMA, 275: 1507–1513 (1996).

    Article  PubMed  CAS  Google Scholar 

  13. Dahlöf B, Hansson L: The influence of antihypertensive therapy on the structural vascular amplifying mechanism in essential hypertension. Different effects of Enalapril and Hydrochlorothiazide. J Hypertens, 10: 1513–1524 (1992).

    Article  PubMed  Google Scholar 

  14. Schulman S, Weiss J Becker L et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. New Eng J Med, 322,19: 1350–1356 (1990).

    Article  PubMed  CAS  Google Scholar 

  15. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Emler P, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR, on behalf of Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA, 270: 713–724 (1993).

    Article  PubMed  CAS  Google Scholar 

  16. Agabiti-Rosei E, Ambrosioni E, DalPalu’ C, Muiesan ML, Zanchetti A on behalf of the RACE Study group. Ace-inhibitor ramipril is more effective than β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens, 13: 1325–1335 (1995).

    Article  PubMed  CAS  Google Scholar 

  17. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study group on antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension Comparison of six antihypertensive agents. The Departement of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation, 95: 2007–2014 (1997).

    Article  PubMed  CAS  Google Scholar 

  18. Trimarco B, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, Lembo G, Condorelli M. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol, 62: 745–750 (1988).

    Article  PubMed  CAS  Google Scholar 

  19. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med, 87: 22–27 (1989).

    Article  PubMed  CAS  Google Scholar 

  20. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and revedelopment of hypertension. J. Cardiovasc. Pharmacol, 17: 179s–181s (1991).

    Article  Google Scholar 

  21. Agabiti Rosei E. Romanelli G, Muiesan ML et al. Impaired response of the hypertrophied left ventricle to beta adrenergic stimulation in hypertensive patients. Circulation, 70(Suppl. II): 61 (1984).

    Google Scholar 

  22. Grassi G, Gianattasio C, Cleroux J, Cuspidi C, Sampieri L, Mancia G. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension, 12: 227–231 (1988).

    Article  PubMed  CAS  Google Scholar 

  23. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frolich ED. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac disrrhythmias. Arch. Intern. Med, 149: 1263–1267 (1989).

    Article  PubMed  CAS  Google Scholar 

  24. Muiesan ML Rizzoni D, Rulli R, Calebich S, Malerba M, Porteri E, Agabiti-Rosei E. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension. J Hypertens, 11(suppl 5): s300–301 (1993).

    CAS  Google Scholar 

  25. Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin blockade on coronary circulation and coronary reserve. Am J Med, 84: 55–60 (1988).

    Article  PubMed  CAS  Google Scholar 

  26. Levy D, Salomon M, D’Agostino R, Belanger A, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90:1786–93 (1994).

    Article  PubMed  CAS  Google Scholar 

  27. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation, 82(suppl III): III29 (Abstract) (1990).

    Google Scholar 

  28. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy multicenter trial Am J Hypertens, 5 (suppl): 182s–189s (1992).

    PubMed  CAS  Google Scholar 

  29. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in LV mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091–1105 (1995).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Enrico Agabiti-Rosei .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Agabiti-Rosei, E., Muiesan, M.L. (1997). Prognostic Significance of Left Ventricular Hypertrophy Regression. In: Zanchetti, A., Devereux, R.B., Hansson, L., Gorini, S. (eds) Hypertension and the Heart. Advances in Experimental Medicine and Biology, vol 432. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5385-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5385-4_22

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7458-9

  • Online ISBN: 978-1-4615-5385-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics